MedTrace Logo

Cannabis Oil for Pain Effectiveness

NCT03522467 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-09-25

No results posted yet for this study

Summary

This project represents a first systematic, prospective, single-arm cohort study of a safe and effective dosing regimen of an orally administered cannabis oil formulation in a cancer subject population with poorly controlled pain.

Conditions

Interventions

DRUG

MRCP001

MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.

Sponsors & Collaborators

  • Ontario Clinical Oncology Group (OCOG)

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • Aurora Cannabis Inc

    lead INDUSTRY

Principal Investigators

  • Marissa Slaven, MD · Hamilton Health Sciences Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-25
Primary Completion
2020-06-30
Completion
2020-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03522467 on ClinicalTrials.gov